GenSight Biologics S.A. (LON:0RIM)
London
· Delayed Price · Currency is GBP · Price in EUR 0.2045
+0.0040 (2.00%)
At close: Jun 6, 2025
GenSight Biologics Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 1.5 | 1.27 | 2.58 | 5.28 | 4.39 | Upgrade
|
| Other Revenue | 1.13 | 1.7 | 2.28 | 2.43 | 3.05 | Upgrade
|
| Revenue | 2.63 | 2.96 | 4.87 | 7.71 | 7.44 | Upgrade
|
| Revenue Growth (YoY) | -11.44% | -39.07% | -36.89% | 3.62% | 51.53% | Upgrade
|
| Gross Profit | 2.63 | 2.96 | 4.87 | 7.71 | 7.44 | Upgrade
|
| Selling, General & Admin | 6.07 | 13.3 | 13.36 | 12.92 | 9.99 | Upgrade
|
| Research & Development | 12.37 | 19.36 | 19.34 | 22.92 | 22.39 | Upgrade
|
| Operating Expenses | 18.44 | 32.66 | 32.7 | 35.84 | 32.37 | Upgrade
|
| Operating Income | -15.81 | -29.7 | -27.84 | -28.13 | -24.93 | Upgrade
|
| Interest Expense | -1.55 | -3.15 | -2.65 | -2.17 | -1.72 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.19 | -0.21 | 0.65 | 0.37 | -0.09 | Upgrade
|
| Other Non Operating Income (Expenses) | 3.2 | 6.84 | 2.21 | 1.31 | -7.27 | Upgrade
|
| EBT Excluding Unusual Items | -13.98 | -26.22 | -27.62 | -28.62 | -34.01 | Upgrade
|
| Pretax Income | -13.98 | -26.22 | -27.62 | -28.62 | -34.01 | Upgrade
|
| Income Tax Expense | 0.02 | - | 0.01 | 0 | 0 | Upgrade
|
| Net Income | -14 | -26.22 | -27.63 | -28.62 | -34.02 | Upgrade
|
| Net Income to Common | -14 | -26.22 | -27.63 | -28.62 | -34.02 | Upgrade
|
| Shares Outstanding (Basic) | 96 | 48 | 46 | 45 | 35 | Upgrade
|
| Shares Outstanding (Diluted) | 96 | 48 | 46 | 45 | 35 | Upgrade
|
| Shares Change (YoY) | 98.18% | 4.29% | 2.61% | 28.54% | 23.76% | Upgrade
|
| EPS (Basic) | -0.15 | -0.54 | -0.60 | -0.63 | -0.97 | Upgrade
|
| EPS (Diluted) | -0.15 | -0.54 | -0.60 | -0.63 | -0.97 | Upgrade
|
| Free Cash Flow | -12.94 | -24.67 | -34.01 | -17.17 | -15.05 | Upgrade
|
| Free Cash Flow Per Share | -0.14 | -0.51 | -0.73 | -0.38 | -0.43 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -602.44% | -1001.86% | -572.15% | -364.86% | -335.13% | Upgrade
|
| Profit Margin | -533.37% | -884.62% | -567.83% | -371.21% | -457.19% | Upgrade
|
| Free Cash Flow Margin | -492.88% | -832.42% | -698.97% | -222.74% | -202.28% | Upgrade
|
| EBITDA | -15.65 | -27.52 | -26.77 | -27.2 | -24.01 | Upgrade
|
| D&A For EBITDA | 0.16 | 2.18 | 1.06 | 0.93 | 0.93 | Upgrade
|
| EBIT | -15.81 | -29.7 | -27.84 | -28.13 | -24.93 | Upgrade
|
| Revenue as Reported | 2.63 | 2.96 | 4.87 | 7.71 | 7.44 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.